This study evaluates for the first time the effect of the MDM2-p53 binding antagonists Nutlin-3 and RG7388 in combination with rucaparib in wild-type TP53 ovarian cancer cell lines and explores the interplay between the p53 pathway and PARP dependent pathways modulated by rucaparib. This evidence concerns the gene PARP1 and ovarian cancer.